The rapid development of emerging data technologies has injected new vitality into the medical industry .
According to the Arterial Network, recently, GeneDock (Judao Technology) announced the completion of 50 million B round of financing. This round of financing was led by Morningside Capital, Huada Gene, BV Baidu Venture Capital and Recapital Capital.
Previously, GeneDock received the A round of investment from Jingwei China in August 2015, and a year later it received the A+ round of investment from Puhua Capital, Shell Fund and Lenovo Star.
In recent years, with the rapid integration of information technology (IT) and biotechnology (BT), many start-ups have emerged in the field of precision medicine . Among them, GeneDock uniquely focuses on the development of precision medical data technology and platform, and hopes to provide integrated data technology products covering information collection, sample detection and analysis and interpretation for the final clinical application scenarios.
“The precision medicine we understand is a new data-driven medical model based on the close integration of biotechnology (BT) and information technology (IT) for clinical practical needs. Therefore, precision medicine requires medical treatment from a technical approach. + BT+IT's cross-border integration, from the industrial application requires the business flow and data flow of the upstream and downstream organizations are closely connected, GeneDock has been committed to provide better infrastructure and solutions for this cross-border integration and connection." GeneDock CEO Li Xia Said.
Integrated precision medical data operating system
GeneDock was founded in September 2014 and is widely recognized and widely recognized by the industry, starting with the first product, GeneDock SeqFlow (Group Data Production Line). The rapid development of sequencing technology has produced a huge amount of genetic data, and the demand for gene data storage, analysis and interpretation has surged. As the earliest genetic data cloud computing service in China, GeneDock SeqFlow has been stable and efficient after four years of technology research and development and product polishing. Safe genetic data processing capabilities are serving many of the top institutions and companies including Huada Gene, WeGene, Aiji Taikang, Panson, CIGNA, and LinkDoc.
Genetic testing and analysis is the core technology for achieving precision medicine, but it is only one of many aspects from patient consultation to final diagnosis and treatment. Through in-depth collaboration with leading medical institutions and expert teams in the country, GeneDock is aware of the enormous potential of precision medical clinical applications and sees the business collaboration and data technology challenges facing the industry today. Therefore, in 2017, GeneDock chose to expand its business scope and develop data technology products for the precision medical field.
Li Xiayu said: "We are accelerating the development of precision medical data technology and products. Based on the industry's leading genetic data production line (GeneDock SeqFlow omics data production line), we will fully open clinical applications (GeneDock Clinic). , sample testing (GeneDock Lab), analysis and interpretation (GeneDock Link molecular diagnostic collaboration system), build a clinically oriented precision medical data operating system, and explore a new model of data collaboration."
At present, GeneDock is one of the few companies in the industry that can provide accurate medical complete business information systems and data platform solutions for physical hospitals. Therefore, it is possible to save the trouble of the hospital's sub-category bidding and re-docking integration, and greatly improve the efficiency of the implementation of the precision medical system. At the same time, because GeneDock is also serving many genetic testing enterprise customers, it can quickly and accurately complete the upstream and downstream business docking between the enterprise and the hospital.
"We have positioned ourselves as a data infrastructure service provider in the field of precision medicine, providing a bridge between hospitals and enterprises to promote efficient integration between upstream and downstream industries." Li Xiayan said frankly.
GeneDock's precision medical data products have formed a good reputation in the industry. Currently, it has provided accurate medical data platform services to dozens of top medical and scientific research institutions, including the First Affiliated Hospital of the Military Medical University (Southwest Hospital), Shanghai Xinhua Hospital, and Huaxi Hospital. Shanghai Sixth Hospital, Chinese Academy of Medical Sciences Cancer Hospital, China Center for Disease Control and Prevention, Southern Medical University, Academy of Military Medical Sciences, Institute of Microbiology, Chinese Academy of Sciences, etc.
Data intelligence advances precision medicine
Advanced and diverse detection technologies bring explosive growth of medical data, and when doctors face a large amount of information, it is difficult to make accurate analysis and judgment in a short period of time, and it is easy to produce "information fatigue." GeneDock believes that artificial intelligence technology, as a powerful information processing assistant for doctors, can alleviate the heavy information processing work of doctors and return doctors' time to patients and clinical research. At the same time, in the face of serious diseases such as genetic diseases, tumors, infectious diseases, etc., how to promote the knowledge ability of top clinical experts and empower the grassroots, it is necessary to construct a clinical assistant decision-making system by combining artificial intelligence technology. GeneDock is working with several expert teams in the industry to develop diagnostic aided models and decision support systems for disease breakdown.
"We adhere to the data technology partners of experts in the field of precision medicine, give full play to their respective advantages, and jointly use artificial intelligence technology to develop clinical assistant decision-making systems to solve the problem of slow transformation of clinical applications and uneven distribution of medical resources. Hui precision medical treatment." Li Xia said.
Why did the investment institution choose GeneDock?
As the lead investor of this round, Chen Xing Capital, in an interview with Arterial Network, Chen Xingtian, vice president of Morningside Capital, believes that one of GeneDock's greatest strengths is to provide a complete solution related to the genetic data business. At present, traditional companies do big data mining is rarely involved in genetic aspects, hospitals do not have a dedicated data system for this service, and in the future they need such a solution, which will be an incremental market in China, and In the United States where genetic data is more widely used, we have seen the emergence and growth of companies like DNAnexus.
With the declining cost of gene sequencing and the trend of irreversible precision medicine in recent years, the demand for gene sequencing and the demand for data analysis services by medical institutions, pharmaceutical companies and biotechnology companies are increasing, but the bottom-level problem has not yet A good solution is the storage and transmission of genetic data, because the amount of data in genetic data, especially whole-genome sequencing, is huge, and GeneDock just fills this short board. In the future, companies such as GeneDock need to be the infrastructure platform for precision medicine, connecting medical institutions and technology companies to achieve the storability and flowability of genetic data, and even vertical applications such as data analysis and interpretation on the platform. Disease prediction models, etc., and then create a micro-ecology of precision medicine, which is also the expectation of Jing Xutian on the future development of GeneDock.
According to Jing Xutian, investing in GeneDock is another layout of Morningside Capital's field of bioinformatics. Morningside Capital is optimistic about computational science and information technology as a high-quality entrepreneurial project empowering life sciences. The collision will bring huge opportunities for the biomedical field.
Huada Gene and GeneDock were initially linked by the cooperation of data services. After the product technology capability was recognized by the other party, the two sides formed a strategic partnership. When GeneDock launched a new round of financing, Huada Gene quickly and firmly participated in the investment. Huada Gene CEO Yin Wei said that GeneDock technology is solid and the team is reliable, and it is an excellent representative in the field of Chinese gene cloud computing. From domestic sequencing instruments to gene cloud computing, the world needs Chinese power. I hope that GeneDock will make more breakthroughs in technical research and application scenarios.
BV Baidu Ventures said: BV has long been concerned about the development of precision medicine driven by genetic data, and has invested in a number of Chinese and American startups in the fields of next-generation sequencing technology, gene precision treatment, gene and new drug discovery. GeneDock, as a platform for carrying and analyzing genetic data, is facing a historical opportunity of rapid development with the rapid increase of the total amount of gene data and the frequency of use, and will bring lower cost and higher data processing efficiency to the whole industry. As a pioneer in the field of genetic computing, GeneDock has deep cooperation with many top hospitals and mainstream gene companies including Huada Gene and WeGene. We expect the company to become the leader in third-party services with the help of the new data axis with great potential. enterprise.
Baidu Venture Capital BV is also very optimistic about the new service model and technology guidance opportunities brought about by the reshaping of the medical market structure in the context of the new medical reform, and will make more layouts in the fields of informationization, insurance, circulation, and grassroots.
Dr. Sun Pengjun, Chairman of Furong Investment, believes that GeneDock has always focused on the group data platform solution. The team has solid technical strength, rich industry experience and excellent strategic vision. It is a rare high-quality startup company in the field of genetic testing. Because the reintegration has been focused on investment in the domestic health sector, especially in the field of precision medicine, it has contributed to this investment. The investment in GeneDock, "We will also inject resources such as research, clinical, project and talents into the road to promote GeneDock to become the most valuable precision medical data platform company in China." Sun Pengjun said.
Chinese herbs have a long history, and we have thousands of years of experience and methods of using herbs. There are countless precious herbs on the land of China, which play a vital role in human life and health. High quality raw materials will benefit more people in today's world driven by modern science and technology. By adopting new modern high technology, the manufacturers extract and purify the essence of the valuable herbs to let more people could benifit it.
Natural herbs, originating from nature, are healthier and more assured. The herb extracts are very excellent raw materials for the health care products.
Our company, Allied, provides various herbal extracts, including ginger extract, pueraria root extract, black wolfberry extract, Angelica root extract, moringa leaf extract, honeysuckle extract, rhodiola rosea extract, Astragalus membranaceus extract, paeony root extract, black garlic powder, matcha powder, etc.
Besides the raw materials, we are also able to custom your own formula upon your unique requirements.
Natural healthy Herb Extracts, Health care product raw materials, black wolfberry extract
Allied Extracts Solutions , https://www.alliedadditives.com